Mucopolysaccharidosis type 2

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Mar 2024Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

Takeda — PHASE2, PHASE3

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

ELAPRASE

Takeda Pharmaceuticals America, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

ELAPRASE

(IDURSULFASE)Orphan drugstandard

Takeda Pharmaceuticals America, Inc.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial
1PHASE2, PHASE3
1Total recruiting
Search clinical trials for Mucopolysaccharidosis type 2

Recent News & Research

1 article
BREAKINGFDAMar 25, 2026

FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome

The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).

Read ↗

Browse all Mucopolysaccharidosis type 2 news →

Specialist Network

Top 6 by expertise

View all Mucopolysaccharidosis type 2 specialists →

Quick Actions